| ID | 1059 |
| Name of the vaccine | Tetravac or Tetravac Acellulaire |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 2 to 24 months |
| Description of the vaccine | Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine, adsorbed. |
| Name of the manufacturer | Sanofi Pasteur |
| Name of the manufacturing country | France |
| Year of manufacture | NA |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Schedule 1: Three primary doses and one booster.
Schedule 2: Three primary doses with no booster. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | Marketing Authorisation Holder : Sanofi Pasteur Europe |
| Approval | Member States of the EEA |
| Adjuvant | Aluminium hydroxide |
| Repurposing | For tetanus, diphtheria and poliomyelitis. |
| Side effects of vaccine | Loss of appetite, irritability, abnormal crying, drowsiness, headache, vomiting, myalgia, redness, pain, swelling, fever and malaise. |
| Post vaccination | NA |
| Dose type | Combination (3 or 4 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.drugs.com/uk/tetravac-suspension-for-injection-leaflet.html |
| Other name | NA |
| Additional Links | NA
|